1. Clinical and virological course of patients with coronavirus disease 2019 in Jiangsu province, China: a retrospective, multi-center cohort study
- Author
-
Rui Huang, Li Zhu, Leyang Xue, Xuebing Yan, Jian Wang, Songping Huang, Biao Zhang, Tianmin Xu, Fang Ji, Chunyang Li, Fang Ming, Yun Zhao, Yang Li, Juan Cheng, Yinling Wang, Huaping Shao, Shuqin Hong, Kang Chen, Xiang-an Zhao, Dawen Sang, Lei Zou, Haiyan Zhao, Xinying Guan, Xiaobing Chen, Biyun Xu, Juan Xia, Yuxin Chen, Xiaomin Yan, Jie Wei, Jiacheng Liu, Longgen Liu, Chuanwu Zhu, and Chao Wu
- Subjects
Coronavirus disease 2019 ,SARS-CoV-2 ,Viral ,Clearance ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Background The clinical and virological course of patients with coronavirus disease 2019 (COVID-19) are lacking. We aimed to describe the clinical and virological characteristics of COVID-19 patients from 10 designated hospitals in 10 cities of Jiangsu province, China. The factors associated with the clearance of SARS-CoV-2 were investigated. Methods A total of 328 hospitalized patients with COVID-19 were retrospectively recruited. The epidemiological, clinical, laboratory, radiology and treatment data were collected. The associated factors of SARS-CoV-2 clearance were analyzed. Results The median duration of hospitalization was 16.0 days (interquartile range [IQR] 13.0–21.0 days). On multivariate Cox regression analysis, age > 60 years (hazard ratio [HR] 0.643, 95% confidence interval [CI] 0.454–0.911, P = 0.013) was associated with the delayed SARS-CoV-2 clearance, while the atomized inhalation of interferon α-2b could improve the clearance of SARS-CoV-2 (HR, 1.357, 95% CI 1.050–1.755, P = 0.020). Twenty-six (7.9%) patients developed respiratory failure and 4 (1.2%) patients developed ARDS. Twenty (6.1%) patients were admitted to the ICU, while no patient was deceased. Conclusions Our study found that age > 60 years was associated with the delayed SARS-CoV-2 clearance, while treated with atomized inhalation of interferon α-2b could promote the clearance of SARS-CoV-2.
- Published
- 2021
- Full Text
- View/download PDF